 |
 |
Thanks, Ray, for sharing your letter, and for all the info you've been providing. The greatest research and the most beautifully designed trials will be a travesty if the drugs that make it through the pipeline are priced out of reach of all but the wealthiest. With Alzheimer's patients also poised to benefit from Nilotinib, we have the numbers to become a huge force. How can we make our voices heard...? Kathleen On 21 October 2015 at 21:09, Rayilyn Brown <[log in to unmask]> wrote: > If you’d like to join me in letting Carrie Scott, Global Head, > Corporate Responsibility Communications and Reporting, know what you > think of Novartis cost of $10,000 a month for nilotinib, a cancer drug > that has dramatically helped late stage Parkinson patients in a Phase 1 > trial. > > her email is: > > [log in to unmask] > > I understand that the drugs developer Dr. Brian Druker received a taxpayer > funded NIH grant to do the research. > > Novartis mission statement is patient “caring and curing”. How is > this possible at $125,000 year for a drug patients can’t afford ? > > If you do decide to express yourself, please just cc me with your > comments. Feel free to use anything I have written or email me if you > have questions. Trials are planned for Alzheimers too. > > How awful if there is hope,, but only for the rich. > > > Ray > Rayilyn Brown > Past Director AZNPF > Arizona Chapter National Parkinson Foundation > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn